Use of Histones for Therapeutic Purposes

Abstract

The invention relates to the use of at least one human recombinant histone, especially at least one histone H1 subtype, and/or a therapeutic histone fraction as a basis for the treatment of thrombocytopenia.

1 - 7 . (canceled) 
     
     
         8 . A method for treating thrombocytopenia in a patient in need thereof, the method comprising: administering to the patient at least three doses of a pharmaceutical composition comprising histone H1.3 or a therapeutically active histone H1.3 segment during a period of at least 8 days, wherein administration of the pharmaceutical composition increases the number of platelets in the peripheral blood, thereby treating the thrombocytopenia. 
     
     
         9 . The method according to  claim 8 , wherein the thrombocytopenia results from a hematological disorder. 
     
     
         10 . The method according to  claim 9 , wherein the hematological disorder is a leukemia. 
     
     
         11 . The method according to  claim 10 , wherein the leukemia is an acute myeloid leukemia. 
     
     
         12 . The method according to  claim 8 , wherein the treatment of the thrombocytopenia occurs concurrently with or after a therapy for a hematological disorder. 
     
     
         13 . The method according to  claim 12 , wherein the therapy is a chemotherapy. 
     
     
         14 . The method according to  claim 12 , wherein the hematological disorder is a leukemia. 
     
     
         15 . The method according to  claim 14 , wherein the leukemia is an acute myeloid leukemia. 
     
     
         16 . The method according to  claim 8 , wherein the administration is intravenous. 
     
     
         17 . The method according to  claim 8 , further comprising the administration of other human recombinant subtypes of histone H1 in combination with the histone H1.3 or therapeutically active histone H1.3 segment. 
     
     
         18 . A method for treating thrombocytopenia in a patient in need thereof caused by a primary disorder, comprising: administering to the patient a pharmaceutical composition comprising histone H1.3 or a therapeutically active histone H1.3 segment, wherein the histone H1.3 is not effective to treat the primary disorder. 
     
     
         19 . The method according to  claim 18 , wherein the thrombocytopenia results from a hematological disorder. 
     
     
         20 . The method according to  claim 18 , wherein the treatment of the thrombocytopenia occurs concurrently with or after a therapy for a hematological disorder. 
     
     
         21 . The method according to  claim 20 , wherein the therapy is a chemotherapy. 
     
     
         22 . The method according to  claim 18 , wherein administration to the patient is administration of at least three doses of a pharmaceutical composition comprising histone H 1 . 3  or a therapeutically active histone H 1 . 3  segment during a period of at least  8  days. 
     
     
         23 . The method according to  claim 18 , wherein the administration is intravenous. 
     
     
         24 . The method according to  claim 18 , further comprising the administration of other human recombinant subtypes of histone H1 in combination with the histone H1.3 or therapeutically active histone H1.3 segment. 
     
     
         25 . A method for treating threatening or incipient thrombocytopenia in a patient which is expected to be caused by chemotherapy, comprising: administering to the patient a pharmaceutical composition comprising histone H1.3 or a therapeutically active histone H1.3 segment concurrently with chemotherapy. 
     
     
         26 . The method according to  claim 25 , wherein the administration is intravenous. 
     
     
         27 . The method according to  claim 25 , further comprising the administration of other human recombinant subtypes of histone H1 in combination with the histone H1.3 or therapeutically active histone H1.3 segment.